Last Updated : May 5, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | |||
| Botox | onabotulinumtoxinA | Migraine, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cresemba | isavuconazole | Treatment of invasive aspergillosis and mucormycosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fulphila | pegfilgrastim | Febrile neutropenia in non-myeloid malignancies | N/A | Complete | ||
| Semglee | insulin glargine | Diabetes mellitus, Type 1 & 2 | Withdrawn | |||
| Delstrigo | doravirine lamuvidine tenofovir disoproxil fumarate | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ozempic | semaglutide | Diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 5, 2024